SKF-82958

SKF-82958 is a **synthetic small molecule** of the benzazepine class that acts as a **full agonist at dopamine D1 and D5 receptors**, with high selectivity and efficacy, and is widely used in research on dopamine signaling and neuropharmacology[1][7][9]. It is also reported to function as a **subtype-selective estrogen receptor-alpha (ERα) agonist**, exhibiting agonist activity at ERα but not ERβ[3][9]. It is supplied mainly for research use and has no approved clinical indications. Developer information is limited, but it was developed for research by Smith Kline & French, now part of GSK[9].

Other names

3-Allyl-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine3-Allyl-6-chloro-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol9-chloro-5-phenyl-3-prop-2-enyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol